Immunoglobulins are unique biologic medicines that can be either infused or injected to treat rare, life-threatening, chronic, and genetic diseases. These diseases include bleeding disorders, immune deficiencies, pulmonary disorders, neurological disorders, and infectious diseases such as tetanus, hepatitis, and rabies. Factors such as growing use of immunoglobulins in primary immunodeficiency disorders and widespread opportunities for immunoglobulins in the treatment of secondary immunodeficiency diseases such as AIDS are responsible for growth of the subcutaneous immunoglobulin market. Better access to medicines in emerging markets due to increasing government support, increase in new indications in the geriatric population, and the development of new plasma-derived formulations are likely to drive the subcutaneous immunoglobulin market.

Transparency Market Research estimates that the subcutaneous immunoglobulin market will expand at a CAGR of 14.0% over the forecast period between 2016 and 2024. Escalating at this pace, the market, which had a valuation of US$2,762.2 Mn in 2015 in terms of revenue, is projected to rise to US$8,831.3 Mn by 2024.

PIDDs to Dominate Demand from Subcutaneous Immunoglobulin Market

The subcutaneous immunoglobulin market has been assessed in terms of application and end user. In terms of application, the subcutaneous immunoglobulin market is categorized into primary immunodeficiency diseases, secondary immunodeficiency diseases, and others. In terms of revenue, primary immunodeficiency diseases held the largest share in 2015 and are projected to dominate the market during the forecast period. Primary immunodeficiency diseases held a share of 68.9% in 2015. The dominance of the segment can be attributed to the rising prevalence of primary immunodeficiency diseases (PIDDs), growing indication of subcutaneous immunoglobulin, and rising research and development activities in the field of plasma derived therapeutics.

In terms of end users, the subcutaneous immunoglobulin market is segmented into hospitals, home care, and clinics. The home care segment is expected to gather significant revenue during the forecast period from 2016 to 2024. Subcutaneous infusion of immunoglobulin is rapidly gaining preference over intravenous route of administration. SCIG can be self-administered once a patient has been trained by a health care professional. Immunoglobulin administration through subcutaneous route has demonstrated to be equally therapeutically effective in preventing infections and has considerably low risk. Home care accounted for US$1.7 bn in the global subcutaneous immunoglobulin market in 2015 and is likely to remain a leading contributor over the 2016-2024 forecast period.

North America Likely to Dominate due to Widespread Support for Healthcare Technology Upgrades

Geographically, subcutaneous immunoglobulin market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America dominated the subcutaneous immunoglobulin market in terms of revenue in 2015 and is projected to retain its dominant position during the forecast period from 2016 to 2024. Usage of immunoglobulins is high in North America primarily due to steady approval for new indications and research undertakings, and increasing geriatric population. According to the Immune Deficiency Foundation, currently around 55,000 people in the U.S. with antibody deficiency receive PIDD treatment in the form of intravenous immunoglobulin. Expected launch of immunoglobulins that are presently in clinical trials in the U.S. during the forecast period is likely to boost market growth.

The North America market for subcutaneous immunoglobulin was valued at US$1,059 mn in 2014 and is likely to rise to US$3,525 mn by the end of 2024.

Primary humoral immunodeficiency or primary immune deficiency diseases (PIDD) is a group of disorders in which the immune system of an individual does not function properly. In PIDD patients, the number of antibodies produced in the body is not sufficient, or the ones produced are defective. PIDDs are thus often characterized by increased vulnerability to infections. According to the International Union of Immunological Societies (IUIS), PIDD is a compilation of more than 150 different diseases.

Global Subcutaneous Immunoglobulin Market: Research Methodology

This report on the subcutaneous immunoglobulin market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. Detailed qualitative analysis of factors responsible for driving and restraining market growth and opportunities has been provided in the market overview section. Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year.

Market related factors such as technological developments, product innovation, expansion of healthcare infrastructure facilities around the world, and historical year-on-year growth have been taken into consideration while estimating the market size. Growth rates for each segment within the subcutaneous immunoglobulin market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, product development life cycle, and regulatory requirements. These factors would help the market players to take strategic decisions in order to strengthen their positions and expand their share in the global market.

Global Subcutaneous Immunoglobulin Market: Segmentation

On the basis of application, the subcutaneous immunoglobulin market is categorized into primary immunodeficiency diseases, secondary immunodeficiency diseases and others. In terms of end users, the subcutaneous immunoglobulin market is segmented into hospitals, home care and clinics.

On the basis of geography, the subcutaneous immunoglobulin market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America comprises the U.S. and Canada. Europe comprises Germany, France, U.K., Spain, Italy and Rest of Europe. Asia-Pacific comprises China, India, Japan, Australia and New Zealand and Rest of Asia Pacific. Latin America comprises Brazil, Mexico and Rest of Latin America. Middle East & Africa comprises of GCC Countries, South Africa and Rest of Middle East & Africa.

Global Subcutaneous Immunoglobulin Market: Competitive Dynamics

The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the subcutaneous immunoglobulin market. The report also profiles major players in the subcutaneous immunoglobulin market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Grifols S.A., CSL Behring LLC, Shire Plc., Biotest AG, Kedrion S.p.A., Octapharma AG, Baxalta Incorporated and Talecris Biotherapeutics, Inc.